Business
Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will
About this update from Editas Medicine, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 13, 2021, at 10:50 a.m. ET. A live webcast of the presentation will be available on the Investors section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website for approximately 30 days following the presentation. About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com. Contacts:InvestorsEditas Medicine Investor Relations(617) [email protected] MediaCristi Barnett(617) 401-0113 [email protected] \nSource: Editas Medicine, Inc.","length":2794,"tagName":"div"}]